Eosinophilic asthma is a condition characterized by breathing issues due to increased levels of eosinophils in the bloodstream and the airway. The increased level of these infection-fighting cells can cause inflammation in the body, especially the respiratory system, resulting in eosinophilic asthma. FASENRA® is an FDA-approved treatment option that effectively helps fight the condition. It targets and depletes the high levels of eosinophils in the airway and calms the symptoms.

Role of eosinophils in eosinophilic asthma

Eosinophils are essential for a healthy and functioning immune system. However, some individuals might have high levels of these cells in their system. The high levels of eosinophils in the bloodstream can cause increased inflammation, resulting in an asthma attack. This condition is known as eosinophilic asthma. It is a fairly common condition and affects a significant number of patients affected by asthma. To help determine the type of asthma that affects a person, they can ask the doctors about their eosinophil count. Also, a blood test can help confirm the diagnosis.

How does FASENRA® work?

Eosinophils are a type of white blood cell that fights infections and helps keep the body healthy. When these immune cells increase in number, they can cause high levels of inflammation in the body. In eosinophilic asthma, increased eosinophils are found in both the blood of the patients as well as the phlegm in their lungs. FASENRA® contains benralizumab as its active ingredient. It is a monoclonal antibody that attaches to the interleukin-5 receptors found on the surface of these white blood cells. When it enters the system, it activates the immune system, and the attached eosinophils are destroyed. This calms down the inflammation in the body, thereby improving the patient’s symptoms and reducing asthma attacks.

FASENRA® is designed to target eosinophils floating freely in the bloodstream and the phlegm in the lungs. It helps eliminate these cells and lowers the level of inflammation in the body. However, before opting for this treatment method, it is always advised to speak to the doctor and then decide on the dosage and usage. The doctor can suggest using FASENRA® in addition to the ongoing treatment, depending on the patient’s condition. Eosinophilic asthma treatment often involves the use of oral corticosteroids to help manage the symptoms. This is in combination with asthma medicines and inhalers that assist in keeping breathing problems under control.

Benefits of FASENRA® for patients with eosinophilic asthma

FASENRA® is an FDA-approved treatment that has been proven effective in improving the patient’s lung function. This means that the patients can breathe better, and their asthma attacks can be managed better in terms of severity or frequency. It is believed that using this medication can also help patients lower their dependence on steroid treatments. FASENRA® is a prescription medicine, and the company advises patients to take one dose every 8 weeks. However, consulting a healthcare provider is advisable to determine the dosage that would work best for the affected person.